Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial.

What Was Tested

Researchers studied Benzazepines in this randomized controlled trial publication.

Hyponatremia predicts poor outcome in patients with acute heart failure syndromes.

This study evaluated the relationship between baseline serum sodium, change in serum sodium, and 60-day mortality in hospitalized heart failure patients.

Who Took Part

According to the abstract, 319 patients were involved.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Benzazepines and who got the comparison, which limits bias.

The comparison arm used a placebo, so changes seen with Benzazepines could be set against what happens without it.

A post-hoc analysis of the ACTIV in CHF trial was performed.

What Was Measured

Hyponatremia predicts poor outcome in patients with acute heart failure syndromes.

This study evaluated the relationship between baseline serum sodium, change in serum sodium, and 60-day mortality in hospitalized heart failure patients.

The subject headings attached to it are Benzazepines, Heart Failure, Hyponatremia, Receptors, Vasopressin, Sodium, Survival Rate and Tolvaptan.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Benzazepines in 319 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2007 (Acute cardiac care), a journal based in England.

More context: all human trials.